Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03461354 · ClinicalTrials.gov registry record · NA
MucoLox Formulation to Mitigate Mucositis Symptoms in Head/Neck Cancer
A NA study, sponsored by Wake Forest University Health Sciences.
- Terminated
- Registry status
- NA
- Development phase
- 49
- Enrollment target
NCT03461354 is a NA study that was terminated before completion, run by Wake Forest University Health Sciences. The registered enrollment target is 49 participants.
The verdict
NCT03461354, a NA study, was terminated before completion, sponsored by Wake Forest University Health Sciences.
- TERMINATED
- Registry status
- NA
- Development phase
- 49 participants
- Enrollment target
Study Summary
This study will examine if the administration of prophylactic MucoLox formulation versus sodium bicarbonate mouthwash in subjects with head/neck cancer receiving radiation ± chemotherapy will result in significantly fewer subjects experiencing severe mucositis.
Interventions
- OTHER Sodium Bicarbonate
- OTHER MucoLox
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2018-04-09 |
| Est. Completion | 2024-04-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03461354
The ClinicalTrials.gov registry entry for NCT03461354 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sodium Bicarbonate is the first listed.
NCT03461354 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03461354 about?
NCT03461354 is a clinical study titled "MucoLox Formulation to Mitigate Mucositis Symptoms in Head/Neck Cancer". This study will examine if the administration of prophylactic MucoLox formulation versus sodium bicarbonate mouthwash in subjects with head/neck cancer receiving radiation ± chemotherapy will result in significantly fewer subjects experiencing severe mucositis.
What is the current status of trial NCT03461354?
This trial is currently terminated. It is a NA study. The enrollment target is 49 participants. The study started on 2018-04-09. Estimated completion is 2024-04-01.
What interventions are being tested in trial NCT03461354?
The interventions under investigation include: Sodium Bicarbonate (OTHER), MucoLox (OTHER).
Who is sponsoring clinical trial NCT03461354?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.